-
-
-
-
-
-
-
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Cingulate reports positive phase 3 trial results for ADHD drug CTx-1301
-
-
-
-
-
-
-
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
15,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

